Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Gilead And Spring Bank Set Second Trial Collaboration In HBV

Executive Summary

Analyst speculates that Gilead could move to acquire Spring Bank if combo trial yields promising data for functional cure of hepatitis B. Eisai in-licenses PARP inhibitor with potential in breast cancer from Oncology Venture, while Sunovion out-licenses three corticosteroid products to Covis.

Advertisement

Related Content

Provenge To Drive Sanpower Growth And Wider China Cell Therapy Market?
Without J&J, Capricor Plans To Advance Progenitor Cell Therapy In DMD
Flu Vax Giant Sanofi Defends Corner With $650m Protein Sciences Buy
Try, Try Again: Bain And Cinven File Fresh Bid For Stada
Shield Pilots Ironclad Specialty Future With Feraccru
Eisai Predicts "Mayhem" For Kisplyx After NICE Finally Okays Halaven
Gilead HIV Sales Getting Boost From Switches To TAF-Based Combos

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC099133

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel